“…Two studies demonstrated clinically important improvements or minimally important differences (change in visual analog scale score of ±7 points from baseline) after treatment with 2L cabazitaxel or 1L or 2L enzalutamide (49,58). Overall, HRQoL, as measured using FACT-G/P, was found to be either maintained or improved by treatments (including Ra-223, cabazitaxel, abiraterone, enzalutamide, docetaxel) in 55%-80% of patients (Table 4) (49,58,59,61,64,65). Clinically relevant improvements in scores of FACT-P or its subscales, including physical well-being, social well-being, emotional well-being, functional well-being, and prostate-specific concerns, were also observed in some studies (Table 4) (58,60,65).…”